{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:16Z","timestamp":1772119516731,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10637-025-01587-8","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:32:33Z","timestamp":1760797953000},"page":"1166-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells"],"prefix":"10.1007","volume":"43","author":[{"given":"Arianna","family":"Bandini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Biso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Viaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Carli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Banchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"issue":"5","key":"1587_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK (2012M 1) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201\u20131206","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1587_CR2","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bbi.2012.06.009","volume":"26","author":"CR Schultze-Florey","year":"2012","unstructured":"Schultze-Florey CR, Mart\u00ednez-Maza O, Magpantay L, Breen EC, Irwin MR, G\u00fcndel H et al (2012) When grief makes you sick: bereavement induced systemic inflammation is a question of genotype. Brain Behav Immun 26(7):1066\u20131071","journal-title":"Brain Behav Immun"},{"issue":"2","key":"1587_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00432-016-2278-1","volume":"143","author":"M Coelho","year":"2017","unstructured":"Coelho M, Soares-Silva C, Brand\u00e3o D, Marino F, Cosentino M, Ribeiro L (2017F 5) \u03b2-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol 143(2):275\u2013291","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1587_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1615\/CritRevImmunol.2019031188","volume":"39","author":"W Wang","year":"2019","unstructured":"Wang W, Cao X (2019) Beta-adrenergic signaling in tumor immunology and immunotherapy. Crit Rev Immunol 39(2):93\u2013103","journal-title":"Crit Rev Immunol"},{"key":"1587_CR5","doi-asserted-by":"crossref","unstructured":"Peixoto R, Pereira M de L, Oliveira M (2020) Beta-blockers and cancer: where are we? Pharmaceuticals 13(6):105","DOI":"10.3390\/ph13060105"},{"key":"1587_CR6","doi-asserted-by":"crossref","unstructured":"Caparica R, Bruzzone M, Agostinetto E, De Angelis C, F\u00eade \u00c2, Ceppi M et al (2021) Beta-blockers in early-stage breast cancer: A systematic review and meta-analysis. ESMO Open 6(2):100066","DOI":"10.1016\/j.esmoop.2021.100066"},{"key":"1587_CR7","doi-asserted-by":"crossref","unstructured":"Chang A, Botteri E, Gillis RD, L\u00f6fling L, Le CP, Ziegler AI et al (2023) Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Sci Transl Med 15(693)","DOI":"10.1126\/scitranslmed.adf1147"},{"key":"1587_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2023.03.046","volume":"657","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen F, Sun X, Huang Y, Zeng Y, Chen J et al (2023) Sympathetic \u03b22-adrenergic receptor blockade overcomes docetaxel resistance in prostate cancer. Biochem Biophys Res Commun 657:69\u201379","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1587_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0028-3886.152625","volume":"63","author":"S Bir","year":"2015","unstructured":"Bir S, Kalakoti P, Ahmed O, Bollam P, Nanda A (2015) Elucidating the role of incidental use of beta-blockers in patients with metastatic brain tumors in controlling tumor progression and survivability. Neurol India 63(1):19","journal-title":"Neurol India"},{"issue":"5","key":"1587_CR10","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mds616","volume":"24","author":"HM Wang","year":"2013","unstructured":"Wang HM, Liao ZX, Komaki R, Welsh JW, O\u2019Reilly MS, Chang JY et al (2013M) Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312\u20131319","journal-title":"Ann Oncol"},{"key":"1587_CR11","doi-asserted-by":"crossref","unstructured":"De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N et al (2011) Treatment With \u03b2-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171(8)","DOI":"10.1001\/archinternmed.2011.131"},{"issue":"2","key":"1587_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.22.00097","volume":"41","author":"K Spilsbury","year":"2023","unstructured":"Spilsbury K, Tuesley KM, Pearson SA, Coory MD, Donovan P, Steer CB et al (2023J 10) Perioperative beta-blocker supply and survival in women with epithelial ovarian cancer and a history of cardiovascular conditions. J Clin Oncol 41(2):266\u2013275","journal-title":"J Clin Oncol"},{"key":"1587_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","volume":"6","author":"E Pasquier","year":"2016","unstructured":"Pasquier E, Andr\u00e9 N, Street J, Chougule A, Rekhi B, Ghosh J et al (2016) Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine 6:87\u201395","journal-title":"EBioMedicine"},{"issue":"3","key":"1587_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/med.21874","volume":"42","author":"L Filippi","year":"2022","unstructured":"Filippi L, Pini A, Cammalleri M, Bagnoli P, Dal Monte M (2022M 29) \u03b23-Adrenoceptor, a novel player in the round-trip from neonatal diseases to cancer: suggestive clues from embryo. Med Res Rev 42(3):1179\u20131201","journal-title":"Med Res Rev"},{"key":"1587_CR15","doi-asserted-by":"crossref","unstructured":"Lucchesi M, Di Marsico L, Guidotti L, Lulli M, Filippi L, Marracci S et al (2025) Hypoxia-dependent upregulation of VEGF relies on \u03b23-adrenoceptor signaling in human retinal endothelial and M\u00fcller cells. Int J Mol Sci 26(9)","DOI":"10.3390\/ijms26094043"},{"issue":"4","key":"1587_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00210-012-0828-x","volume":"386","author":"M Dal Monte","year":"2013","unstructured":"Dal Monte M, Filippi L, Bagnoli P (2013A 3) Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants. Naunyn Schmiedebergs Arch Pharmacol 386(4):269\u2013278","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"1587_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","volume":"32","author":"JG Baker","year":"2011","unstructured":"Baker JG, Hill SJ, Summers RJ (2011) Evolution of \u03b2-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32(4):227\u2013234","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1587_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1124\/jpet.103.061192","volume":"309","author":"V Leblais","year":"2004","unstructured":"Leblais V, Pourageaud F, Ivorra MD, Guibert C, Marthan R, Muller B (2004) Role of \u03b1-adrenergic receptors in the effect of the \u03b2-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. J Pharmacol Exp Ther 309(1):137\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1587_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1476-5381.2009.00186.x","volume":"158","author":"S Bexis","year":"2009","unstructured":"Bexis S, Docherty JR (2009S 25) Role of \u03b11 and \u03b23-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol 158(1):259\u2013266","journal-title":"Br J Pharmacol"},{"issue":"5\u20136","key":"1587_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00210-006-0127-5","volume":"374","author":"W Vrydag","year":"2007","unstructured":"Vrydag W, Michel MC (2007F 6) Tools to study \u03b23-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374(5\u20136):385\u2013398","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"1587_CR21","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00109-013-1073-6","volume":"91","author":"M Dal Monte","year":"2013","unstructured":"Dal Monte M, Casini G, Filippi L, Nicchia GP, Svelto M, Bagnoli P (2013D 2) Functional involvement of \u03b23-adrenergic receptors in melanoma growth and vascularization. J Mol Med 91(12):1407\u20131419","journal-title":"J Mol Med"},{"key":"1587_CR22","doi-asserted-by":"crossref","unstructured":"Calvani M, Cavallini L, Tondo A, Spinelli V, Ricci L, Pasha A et al (2018) \u03b23\u2010adrenoreceptors control mitochondrial dormancy in melanoma and embryonic stem cells. Oxid Med Cell Longev 2018(1)","DOI":"10.1155\/2018\/6816508"},{"key":"1587_CR23","doi-asserted-by":"crossref","unstructured":"Calvani M, Dabraio A, Bruno G, De Gregorio V, Coronnello M, Bogani C et al (2020) \u03b23-adrenoreceptor blockade reduces hypoxic myeloid leukemic cells survival and chemoresistance. Int J Mol Sci 21(12):4210","DOI":"10.3390\/ijms21124210"},{"key":"1587_CR24","doi-asserted-by":"crossref","unstructured":"Bandini A, Banchi M, Orlandi P, Vaglini F, Al\u00ec G, Fontanini G (2025) Melanocortin-4 receptor antagonism inhibits colorectal and anaplastic thyroid cancer In vitro and In vivo. J Clin Med 14(4):1165","DOI":"10.3390\/jcm14041165"},{"issue":"2","key":"1587_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010J 15) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446","journal-title":"Cancer Res"},{"issue":"18","key":"1587_CR26","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM et al (2016) Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32(18):2866\u20132868","journal-title":"Bioinformatics"},{"issue":"3","key":"1587_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z et al (2022J 1) Synergyfinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics 20(3):587\u2013596","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"5","key":"1587_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK (2012M 1) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201\u20131206","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1587_CR29","doi-asserted-by":"publisher","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","volume":"70","author":"EK Sloan","year":"2010","unstructured":"Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042\u20137052","journal-title":"Cancer Res"},{"issue":"1","key":"1587_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbrc.2019.04.099","volume":"514","author":"J Deng","year":"2019","unstructured":"Deng J, Jiang P, Yang T, Huang M, Qi W, Zhou T et al (2019) Targeting \u03b23-adrenergic receptor signaling inhibits neuroblastoma cell growth via suppressing the mTOR pathway. Biochem Biophys Res Commun 514(1):295\u2013300","journal-title":"Biochem Biophys Res Commun"},{"key":"1587_CR31","doi-asserted-by":"crossref","unstructured":"Boaretto A, Bruno G, Nastasi N, Favre C, Calvani M (2023) Abstract 6721: \u03b23-adrenergic receptor correlates with tumor growth and progression in neuroblastoma. Cancer Res 83(7_Supplement):6721\u20136721","DOI":"10.1158\/1538-7445.AM2023-6721"},{"issue":"2","key":"1587_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1023\/A:1006338232150","volume":"60","author":"TA Slotkin","year":"2000","unstructured":"Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ (2000) \u03b2-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60(2):153\u2013166","journal-title":"Breast Cancer Res Treat"},{"issue":"7\u20138","key":"1587_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18632\/oncoscience.357","volume":"4","author":"SL Rains","year":"2017","unstructured":"Rains SL, Amaya CN, Bryan BA (2017A 23) Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience 4(7\u20138):95\u2013105","journal-title":"Oncoscience"},{"issue":"21","key":"1587_CR34","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.3390\/ijms21217958","volume":"21","author":"B Mravec","year":"2020","unstructured":"Mravec B, Horvathova L, Hunakova L (2020O 26) Neurobiology of cancer: the role of \u03b2-adrenergic receptor signaling in various tumor environments. Int J Mol Sci 21(21):7958","journal-title":"Int J Mol Sci"},{"key":"1587_CR35","doi-asserted-by":"crossref","unstructured":"Orlandi P, Banchi M, Vaglini F, Carli M, Aringhieri S, Bandini A et al (2024) Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib. Biochem Pharmacol 219:115952","DOI":"10.1016\/j.bcp.2023.115952"},{"issue":"12","key":"1587_CR36","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00109-013-1073-6","volume":"91","author":"M Dal Monte","year":"2013","unstructured":"Dal Monte M, Casini G, Filippi L, Nicchia GP, Svelto M, Bagnoli P (2013D 2) Functional involvement of \u03b23-adrenergic receptors in melanoma growth and vascularization. J Mol Med 91(12):1407\u20131419","journal-title":"J Mol Med"},{"key":"1587_CR37","doi-asserted-by":"crossref","unstructured":"Porcelli L, Garofoli M, Di Fonte R, Fucci L, Volpicella M, Strippoli S (2020) The \u03b2-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Sci Rep 10(1):10465","DOI":"10.1038\/s41598-020-67342-6"},{"issue":"2","key":"1587_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00432-016-2278-1","volume":"143","author":"M Coelho","year":"2017","unstructured":"Coelho M, Soares-Silva C, Brand\u00e3o D, Marino F, Cosentino M, Ribeiro L (2017F 5) \u03b2-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol 143(2):275\u2013291","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"1587_CR39","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/modpathol.2012.108","volume":"25","author":"KM Chisholm","year":"2012","unstructured":"Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-Mckenney AE (2012) \u03b2-adrenergic receptor expression in vascular tumors. Mod Pathol 25(11):1446\u20131451","journal-title":"Mod Pathol"},{"key":"1587_CR40","unstructured":"Limaiem F, Kashyap S, Naing PT, Mathias PM, Giwa AO (2024) Anaplastic thyroid cancer"},{"issue":"45","key":"1587_CR41","doi-asserted-by":"publisher","first-page":"32719","DOI":"10.1074\/jbc.M706815200","volume":"282","author":"R Kou","year":"2007","unstructured":"Kou R, Michel T (2007) Epinephrine regulation of the endothelial nitric-oxide synthase. J Biol Chem 282(45):32719\u201332729","journal-title":"J Biol Chem"},{"issue":"4","key":"1587_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/cells8040357","volume":"8","author":"G Schena","year":"2019","unstructured":"Schena G, Caplan MJ (2019A 16) Everything you always wanted to know about \u03b23-AR * (* but were afraid to ask). Cells 8(4):357","journal-title":"Cells"},{"key":"1587_CR43","doi-asserted-by":"crossref","unstructured":"Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G et al (2019) Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines 7(3):69","DOI":"10.3390\/biomedicines7030069"},{"key":"1587_CR44","doi-asserted-by":"crossref","unstructured":"Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito K et al (2016) The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 26(9):1293\u20131299","DOI":"10.1089\/thy.2016.0072"},{"issue":"12","key":"1587_CR45","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom9120789","volume":"9","author":"TM Abu Samaan","year":"2019","unstructured":"Abu Samaan TM, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D (2019N 27) Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules 9(12):789","journal-title":"Biomolecules"},{"issue":"3\u20134","key":"1587_CR46","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10555-013-9433-9","volume":"32","author":"Y Cheng","year":"2013","unstructured":"Cheng Y, Zhang G, Li G (2013D 13) Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev 32(3\u20134):567\u2013584","journal-title":"Cancer Metastasis Rev"},{"key":"1587_CR47","doi-asserted-by":"crossref","unstructured":"Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C et al (2021) The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol 38(6):60","DOI":"10.1007\/s12032-021-01503-z"},{"issue":"10","key":"1587_CR48","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5(10):835\u2013844","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"1587_CR49","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008S 1) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14(17):5459\u20135465","journal-title":"Clin Cancer Res"},{"key":"1587_CR50","doi-asserted-by":"crossref","unstructured":"Barlak N, Sanli F, Celik S, \u0130skender B, Anil DA, Gambacorta N et al (2025) Synthesis and evaluation of sulfonamide-chalcone hybrid compounds as inhibitors of VEGFR1\/VEGFR2- mediated angiogenesis. Bioorg Chem 164:108903","DOI":"10.1016\/j.bioorg.2025.108903"},{"issue":"1","key":"1587_CR51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12885-018-4583-3","volume":"18","author":"J Xiao","year":"2018","unstructured":"Xiao J, Egger ME, McMasters KM, Hao H (2018D 22) Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines. BMC Cancer 18(1):675","journal-title":"BMC Cancer"},{"issue":"36","key":"1587_CR52","doi-asserted-by":"publisher","first-page":"29864","DOI":"10.1039\/D5RA03933A","volume":"15","author":"TN Truong","year":"2025","unstructured":"Truong TN, Canh Pham E, Nguyen Tran NV, Tieu PT, Thi Cao MH, Hong Do TT et al (2025) Synthesis, evaluation of in vitro cytotoxic activity, and in silico studies of some 3-methylenamino-4 3 H-quinazolone derivatives. RSC Adv 15(36):29864\u201329878","journal-title":"RSC Adv"},{"key":"1587_CR53","doi-asserted-by":"crossref","unstructured":"Aoyama M, Takizawa H, Otani T, Inoue S, Kawakita N, Tsuboi M et al (2020) Non-invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small-animal FDG-PET\/CT. Oncol Rep","DOI":"10.3892\/or.2020.7720"},{"issue":"1","key":"1587_CR54","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1186\/s12885-021-08972-5","volume":"21","author":"MTC Poon","year":"2021","unstructured":"Poon MTC, Bruce M, Simpson JE, Hannan CJ, Brennan PM (2021D 18) Temozolomide sensitivity of malignant glioma cell lines \u2013 a systematic review assessing consistencies between in vitro studies. BMC Cancer 21(1):1240","journal-title":"BMC Cancer"},{"issue":"1","key":"1587_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.bjp.0705017","volume":"138","author":"N Brahmadevara","year":"2003","unstructured":"Brahmadevara N, Shaw AM, MacDonald A (2003J 2) Evidence against \u03b23-adrenoceptors or low affinity state of \u03b21-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138(1):99\u2013106","journal-title":"Br J Pharmacol"},{"key":"1587_CR56","doi-asserted-by":"crossref","unstructured":"Tricomi J, Landini L, Nieddu V, Cavallaro U, Baker JG, Papakyriakou A et al (2023) Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships. Eur J Med Chem 246:114961","DOI":"10.1016\/j.ejmech.2022.114961"},{"issue":"6","key":"1587_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00210-005-1067-1","volume":"371","author":"V Leblais","year":"2005","unstructured":"Leblais V, Pourageaud F, Ivorra MD, Marthan R, Muller B (2005J 13) Comparison of the \u03b1-adrenoceptor-mediated effects of \u03b23-adrenoceptor ligands in rat pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 371(6):535\u2013539","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"1587_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CMR.0000000000000943","volume":"34","author":"B Switzer","year":"2024","unstructured":"Switzer B, Puzanov I, Gandhi S, Repasky EA (2024) Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity. Melanoma Res 34(2):89\u201395","journal-title":"Melanoma Res"},{"issue":"7","key":"1587_CR59","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jsps.2023.05.020","volume":"31","author":"J Wawszczyk","year":"2023","unstructured":"Wawszczyk J, Wolan R, Smolik S, Kapral M (2023) In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells. Saudi Pharm J 31(7):1306\u20131316","journal-title":"Saudi Pharm J"},{"issue":"3","key":"1587_CR60","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1096\/fj.15-277798","volume":"30","author":"CK Pon","year":"2016","unstructured":"Pon CK, Lane JR, Sloan EK, Halls ML (2016M 17) The \u03b22-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. FASEB J 30(3):1144\u20131154","journal-title":"FASEB J"},{"issue":"3","key":"1587_CR61","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3892\/ol.2017.6653","volume":"14","author":"JJ He","year":"2017","unstructured":"He JJ, Zhang WH, Liu SL, Chen YF, Liao CX, Shen QQ et al (2017) Activation of \u03b2-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett 14(3):3846\u20133852","journal-title":"Oncol Lett"},{"issue":"3","key":"1587_CR62","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3892\/or.2016.4918","volume":"36","author":"WJ Wei","year":"2016","unstructured":"Wei WJ, Shen CT, Song HJ, Qiu ZL, Luo QY (2016) Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncol Rep 36(3):1576\u20131584","journal-title":"Oncol Rep"},{"key":"1587_CR63","doi-asserted-by":"crossref","unstructured":"Calvani M, Bruno G, Dabraio A, Subbiani A, Bianchini F, Fontani F (2020) \u03b23-adrenoreceptor blockade induces stem cells differentiation in melanoma microenvironment. Int J Mol Sci 21(4):1420","DOI":"10.3390\/ijms21041420"},{"issue":"3","key":"1587_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/ijtm1030021","volume":"1","author":"A Xanthopoulos","year":"2021","unstructured":"Xanthopoulos A, Daskalopoulou I, Frountzi S, Papadimitriou E (2021N 30) A Systematic review on the role of adrenergic receptors in angiogenesis regulation in health and disease. International Journal of Translational Medicine 1(3):353\u2013365","journal-title":"International Journal of Translational Medicine"},{"key":"1587_CR65","doi-asserted-by":"crossref","unstructured":"Porcelli L, Garofoli M, Di Fonte R, Fucci L, Volpicella M, Strippoli S (2020) The \u03b2-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. Sci Rep 10(1):10465","DOI":"10.1038\/s41598-020-67342-6"},{"issue":"1","key":"1587_CR66","doi-asserted-by":"publisher","first-page":"15058","DOI":"10.1038\/s41598-022-18324-3","volume":"12","author":"LM Solern\u00f3","year":"2022","unstructured":"Solern\u00f3 LM, Sobol NT, Gottardo MF, Capobianco CS, Ferrero MR, V\u00e1squez L et al (2022S 8) Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy. Sci Rep 12(1):15058","journal-title":"Sci Rep"},{"issue":"7","key":"1587_CR67","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.18632\/oncotarget.2652","volume":"6","author":"M Calvani","year":"2015","unstructured":"Calvani M, Pelon F, Comito G, Taddei ML, Moretti S, Innocenti S et al (2015) Norepinephrine promotes tumor microenvironment reactivity through \u03b23-adrenoreceptors during melanoma progression. Oncotarget 6(7):4615\u20134632","journal-title":"Oncotarget"},{"key":"1587_CR68","doi-asserted-by":"crossref","unstructured":"Ascone M, Banella C, Amato R, Lotti M, Mattei G, Carrozzo F et al (2024) Abstract A048 SR59230A-induced ferroptosis sensitization of Ewing sarcoma cells via Beta-3 adrenergic receptor modulation: a novel therapeutic target. Cancer Res 84(17_Supplement):A048\u2013A048","DOI":"10.1158\/1538-7445.PEDIATRIC24-A048"},{"key":"1587_CR69","doi-asserted-by":"crossref","unstructured":"Banella C, Zocca L, Boaretto A, Mattei G, Mola M, Ballerini L et al (2023) Abstract A108: Metabolic oriented treatment: efficacy of sr59230a 𝜷3-adrenergic receptor antagonist, and sr plus buformin\u00ae in Ewing sarcoma. Mol Cancer Ther 22(12_Supplement):A108\u2013A108","DOI":"10.1158\/1535-7163.TARG-23-A108"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01587-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:04:23Z","timestamp":1763701463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01587-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01587-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7147623\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}